title: [Statin therapy for atherogenic hypertriglyceridemia].
abstract: LDL-cholesterol lowering by statins substantially reduces morbidity and mortality of coronary heart disease (CHD) and ischemic stroke. Statins are the most potent agents for lowering circulating LDL particles. Accumulation of triglyceride-rich remnant lipoproteins in both fasting and postprandial state is strongly associated with the formation of highly atherogenic small dense LDL. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statin, strong statins such as rosuvastatin, atorvastatin, and pitavastatin, can reduce the triglyceride and small dense LDL greater than other statins. Statin is one of the first-line drugs for management of hypertriglyceridemia with elevated LDL-cholesterol and/or non HDL-cholesterol. Aggressive LDL-cholesterol lowering may be required for the management of high-risk CHD patients with both high LDL-cholesterol and triglyceride.
authors.affiliation: Division of Cardiology, Department of Medicine, Showa University School of Medicine.
authors.forename: Shinji
authors.initials: S
authors.lastname: Koba
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides